- Home
- WBS vs PCVX Comparison
WBS vs PCVX Comparison
Compare WBS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBS
- PCVX
- Stock Information
- Founded
- WBS 1935
- PCVX 2013
- Country
- WBS United States
- PCVX United States
- Employees
- WBS N/A
- PCVX N/A
- Industry
- WBS Major Banks
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- WBS Finance
- PCVX Health Care
- Exchange
- WBS Nasdaq
- PCVX Nasdaq
- Market Cap
- WBS 8.9B
- PCVX 4.4B
- IPO Year
- WBS N/A
- PCVX 2020
- Fundamental
- Price
- WBS $59.61
- PCVX $34.50
- Analyst Decision
- WBS Buy
- PCVX Strong Buy
- Analyst Count
- WBS 12
- PCVX 10
- Target Price
- WBS $65.42
- PCVX $136.50
- AVG Volume (30 Days)
- WBS 1.4M
- PCVX 1.5M
- Earning Date
- WBS 07-17-2025
- PCVX 08-05-2025
- Dividend Yield
- WBS 2.71%
- PCVX N/A
- EPS Growth
- WBS N/A
- PCVX N/A
- EPS
- WBS 4.44
- PCVX N/A
- Revenue
- WBS $2,372,492,000.00
- PCVX N/A
- Revenue This Year
- WBS $9.68
- PCVX N/A
- Revenue Next Year
- WBS $5.20
- PCVX N/A
- P/E Ratio
- WBS $13.30
- PCVX N/A
- Revenue Growth
- WBS N/A
- PCVX N/A
- 52 Week Low
- WBS $39.43
- PCVX $27.66
- 52 Week High
- WBS $63.99
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- WBS 72.78
- PCVX 53.91
- Support Level
- WBS $57.59
- PCVX $31.79
- Resistance Level
- WBS $54.54
- PCVX $34.63
- Average True Range (ATR)
- WBS 1.28
- PCVX 1.38
- MACD
- WBS 0.55
- PCVX 0.09
- Stochastic Oscillator
- WBS 91.66
- PCVX 86.31
About WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.